Evaluation of Insulin Sensitivity in Clinical Practice and in Research Settings

Nutrition Reviews

Volumn 61, Issue 12, 2003, Pages 397-412

  Monzillo, Lais U ^a   Hamdy, Osama ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Clinical practice; Insulin resistance; Insulin sensitivity

Indexed keywords

INSULIN;

BLOOD; DIABETIC OBESITY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE TEST; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; INTRAVENOUS GLUCOSE TOLERANCE TEST; MATHEMATICAL MODEL; METABOLIC SYNDROME X; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL VALUE; ORAL GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; RADIOIMMUNOASSAY; REVIEW; RISK REDUCTION; UNITED STATES;

BLOOD GLUCOSE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; EVALUATION STUDIES; GLUCOSE TOLERANCE TEST; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INSULIN; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; RISK REDUCTION BEHAVIOR; UNITED STATES;

EID: 0942287757     PISSN: 00296643     EISSN: None     Source Type: Journal    
DOI: 10.1301/nr.2003.dec.397-412     Document Type: Review

References (161)

1. Caro JF. Clinical review 26. Insulin resistance in obese and nonobese man. J Clin Endocrinol Metab. 1991;73:691-696.
2. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
3. DeFronzo RA, Ferrannini MD. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-194.
4. Ferrannini E, Natali A. Essential hypertension, metabolic disorders, and insulin resistance. Am Heart J. 1991;121:1274-1282.
5. Moller DE, Flier JS. Insulin resistance-mechanisms, syndromes, and implications. N Engl J Med. 1991;325:938-948.
6. Laakso M, Sarlund H, Salonen R, et al. Asymptomatic atherosclerosis and insulin resistance. Arterioscler Thromb. 1991;11:1068-1076.
7. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia. 1991; 34:416-422.
8. Lindahl B, Asplund K, Hallmans G. High serum insulin, insulin resistance and their associations with cardiovascular risk factors. The Northern Sweden MONICA population study. J Intern Med. 1993;234:263-270.
9. Welborn TA, Wearne K. Coronary heart disease and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care. 1979;2:154-160.
10. Eschwege E., Richard JL, Thibult N, et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later. Horm Metab Res. 1985;15:41-46.
11. Pyörälä K, Savolainen E, Kaukola S, Haapakoski J. Plasma insulin as coronary heart disease risk factor: relationships to other risk factors and predictive value during 9 1/2 year follow-up of the Helsinki Policemen Study population. Acta Med Scand. 1985;701:38-52.
12. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
13. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. JAMA. 2002;287:356-359.
14. Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise: the 6-year Malmo feasibility study. Diabetologia. 1991;34:891-898.
15. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537-544.
16. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
17. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
18. Niskanen L, Uusitupa M, Sarlund H, Siitonen O, Paljarvi L, Laakso M. The effects of weight loss on insulin sensitivity, skeletal muscle composition and capillary density in obese non-diabetic subjects. Int J Obes Relat Metab Disord. 1996;20:154-160.
19. Weinstock RS, Dai H, Wadden TA. Diet and exercise in the treatment of obesity: effects of 3 interventions on insulin resistance. Arch Intern Med. 1998;158:2477-2483.
20. Perseghin G, Price TB, Petersen KF, et al. Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin resistant subjects. N Engl J Med. 1996; 335:1357-1362.
21. Mayer-Davis EJ, D'Agostino RJ, Karter AJ, et al. Intensity and amount of physical activity in relation to insulin sensitivity: the Insulin Resistance Atherosclerosis Study. JAMA. 1998;279:669-674.
22. Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol. 1998;138:269-274.
23. Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism. 2001;50:1457-1461.
24. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky JM. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994;331:1188-1193.
25. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R. The insulin sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol. 1996;81:3299-3306.
26. Berkowitz K, Peters R, Kjos SL, et al. Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM. Diabetes. 1996;45:1572-1579.
27. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Moralles PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes. 1992;41:715-722.
28. Zavaroni I, Bonora E, Pagliara M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med. 1989;320:702-706.
29. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334: 952-957.
30. Fontbonne A, Charles MA, Thibult N, et al. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia. 1991;34:356-361.
31. Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care. 2000;23: 171-175.
32. Laakso M. How good a marker is insulin level for insulin resistance? Am J. Epidemiol. 1992;137: 959-965.
33. Ferrannini E, Mari A. How to measure insulin sensitivity. J Hypertens. 1998;16:895-906.
34. American Diabetes Association. Consensus development conference on insulin resistance. Diabetes Care. 1998;21:310-314.
35. Anderson RL, Hamman RF, Savage PJ, et al. Exploration of simple insulin sensitivity measures derived from frequently sampled intravenous glucose tolerance (FSIGT) tests. The Insulin Resistance Atherosclerosis Study. Am J Epidemiol. 1995;142: 724-732.
36. Phillips DIW, Clark PM, Hales CN, Osmond C. Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med. 1994;11:286-292.
37. Yoshioka N, Kusuya T, Matsuda A, Taniguchi M, Iwamoto Y. Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1988;31:355-360.
38. Davis M, Rayman G, Gray IP, Day GL, Hales CN. Insulin deficiency and increased plasma concentrations of intact and 32/33 split proinsulin in subjects with impaired glucose tolerance. Diabet Med. 1993;10:313-320.
39. Mykkänen L, Haffner S, Hales C, Rönnemaa T, Laakso M. The relation of proinsulin, insulin, and proinsulin-to-insulin ratio to insulin sensitivity and acute insulin response in normoglycemic subjects. Diabetes. 1997;46:1990-1995.
40. Deberg M, Houssa P, Frank BH, Sodoyez-Goffaux F, Sodoyez JC. Highly specific radioimmunoassay for human insulin based on immune exclusion of all insulin precursors. Clin Chem. 1998;44:1504-1513.
41. Chevenne D, Trivin F, Porquet D. Insulin assays and reference values. Diabetes Metab. 1999;25: 459-476.
42. Armitage M, Wilkin T, Wood P, Casey C, Loveless R. Insulin autoantibodies and insulin assay. Diabetes. 1988;37:1392-1396.
43. Boyns DR, Crossley JN, Abrams ME, Jarrett RJ, Keen H. Oral glucose tolerance and related factors in a normal population sample. Blood sugar, plasma insulin, glyceride, and cholesterol measurements and the effects of age and sex. BMJ. 1969;1:595-598.
44. Bonora E, Zavaroni I, Alpi O, et al. Insulin and C-peptide responses to 75gr oral glucose load in the healthy man. Diabetes Metab. 1986;12:143-148.
45. McAuley KA, Williams SM, Mann JI, et al. Diagnosing insulin resistance in the general population. Diabetes Care. 2001;24:460-464.
46. Ascaso JF, Romero P, Real JT, Priego A, Valdecabres C, Carmena R. Insulin resistance quantification by fasting insulin plasma values and HOMA index in a non-diabetic population. Med Clin. 2001; 117:530-533.
47. American Diabetes Association. Task Force on Standardization of the Insulin Assay (Task Force Report). Diabetes. 1996;45:242-246.
48. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
49. Emoto M, Kawagishi T, Nishizawa Y, et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulphonylureas. Diabetes Care. 1999; 22:818-822.
50. Matsuda M, DeFronzo R. Insulin sensitivity indices obtained from oral glucose tolerance testing. Comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462-1470.
51. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care. 2000;23:57-63.
52. Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders. The Bruneck Study. Diabetes. 1998;17:2643-2649.
53. Katsuki A, Sumida Y, Gabazza EC, et al. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care. 2001;24:362-365.
54. Fukushima M, Taniguchi A, Sakai M, et al. Assessment of insulin sensitivity. Diabetes Care. 2000;23: 1038-1039.
55. Hermans MP, Levy JC, Morris RJ, Turner RC. Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia. 1999;42:678-687.
56. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ. A model-based method for assessing insulin sensitivity from the OGTT. Diabetes Care. 2001;4:539-548.
57. Brun JF, Raynaud E, Mercier J. Homeostasis model assessment and related simplified evaluations of insulin sensitivity from fasting insulin and glucose. Diabetes Care. 2000;23:1037-1038.
58. Hanson RL, Pratley RE, Bogardus C, et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol. 2000;151:190-198.
59. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402-2410.
60. Perseghin G, Caumo A, Caloni M, Testolin G, Luzi L. Incorporation of the fasting plasma FFA concentration into QUICKI improves its association with insulin sensitivity in nonobese individuals. J Clin Endocrinol Metab. 2001;86:4776-4781.
61. Hrebicek J, Janout V, Mallincikova J, Horakova D, Cizek L. Detection of insulin resistance by simple quantitative insulin sensitivity check index QUICKI for epidemiological assessment and prevention. J Clin Endocrinol Metab. 2002;87:144-147.
62. Abbasi F, Reaven GM. Evaluation of the quantitative insulin sensitivity check index as an estimate of insulin sensitivity in humans. Metabolism. 2002; 51:235-237.
63. Kirwan JP, Huston-Presley L, Kalhan SC, Catalano PM. Clinically useful estimates of insulin sensitivity during pregnancy: validation studies in women with normal glucose tolerance and gestational diabetes. Diabetes Care. 2001;24:1602-1607.
64. Bastard JP, Robert JJ, Jardel C, Bruckert E, Grimaldi, A, Hainque B. Is quantitative insulin sensitivity check index, a far insulin sensitivity index in humans? Diabetes Metab. 2001;27:69-70.
65. Mather KJ, Hunt AE, Steinberg HO, et al. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab. 2001;86:5457-5464.
66. Quon MJ. QUICKI is a useful and accurate index of insulin sensitivity. J Clin Endocrinol Metab. 2002; 87:949-950.
67. Duncan GE, Hutson AD, Stacpoole PW. QUICKI is not a useful and accurate index of insulin sensitivity following exercise training. J Clin Endocrinol Metab. 2002;87:950-951.
68. Radziuk J. Insulin sensitivity and its measurements: structural commonalities among the methods. J Clin Endocrinol Metab. 2000;85:4426-4433.
69. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;28:412-419.
70. Nipjels G, Van der Wal PS, Bouter LM, Heine RJ. Comparison of three methods for the quantification of beta-cell function and insulin sensitivity. Diabetes Res Clin Pract. 1994;26:189-195.
71. Silfen ME, Manibo AM, McMahon DJ, Levine LS, Murphy AR, Oberfield SE. Comparison of simple measures of insulin sensitivity in young girls with premature adrenarche: the fasting glucose to insulin ratio may be a simple and useful measure. J Clin Endocrinol Metab. 2001;86:2863-2868.
72. Vuguin P, Saenger P, Dimatino-Nardi J. Fasting glucose insulin ratio: a useful measure of insulin resistance in girls with premature adrenarche. J Endocrinol Metab. 2001;86:4618-4621.
73. Guerrero-Romero F, Rodriguez-Moran M. Glucose intolerance is predicted by the high fasting insulin-to-glucose ratio. Diabetes Metab. 2001;27:117-121.
74. Guercio G, Rivarola MA, Chaler E, Maceiras M, Belgorosky A. Relationship between the GH/IGF-I axis, insulin sensitivity, and adrenal androgens in normal prepubertal and pubertal boys. J Clin Endocrinol Metab. 2002;87:1162-1169.
75. Parra A, Ramirez A, Espinosa de los Monteros A. Fasting glucose/insulin ratio. An index to differentiate normo from hyperinsulinemic women with polycystic ovary syndrome. Rev Invest Clin. 1994; 46:363-368.
76. Quon MJ. Limitations of the fasting glucose to insulin ratio as an index of insulin sensitivity. J Clin Endocrinol Metab. 2001;86:4615-4617.
77. Hosker JP, Matthews DR, Rudenski AS, et al. Continuous infusion of glucose with model assessment: measurement of insulin resistance and beta-cell function in man. Diabetologia. 1985;28:401-411.
78. Dale PO, Tanbo T, Vaaler S, Abyholm T. Body weight, hyperinsulinemia, and gonadotropin levels in the polycystic ovarian syndrome: evidence of two distinct populations. Fertil Steril. 1992;58:487-491.
79. Hosker JP, Kumar S, Gordon C, Bhatnagar D, France M, Boulton AJ. Diet treatment of newly presenting type 2 diabetes improves insulin secretory capacity, but has no effect on insulin sensitivity. Diabet Med. 1993;10:509-513.
80. Jaap AJ, Shore AC, Tooke JE. Relationship of insulin resistance to microvascular dysfunction in subjects with fasting hyperglycaemia. Diabetologia. 1997;40:238-243.
81. Dale PO, Tanbo T, Haug E, Abyholm T. The impact of insulin resistance on the outcome of ovulation induction with low-dose follicle stimulating hormone in women with polycystic ovary syndrome. Hum Reprod. 1998;13:567-570.
82. Smets YF, van der Pijl JW, Frolich M, Ringers J, de Fijter JW, Lemkes HH. Insulin secretion and sensitivity after simultaneous pancreas-kidney transplantation estimated by continuous infusion of glucose with model assessment. Transplantation. 2000;69:1322-1327.
83. Fedorcsak P, Dale PO, Storeng R, Tanbo T, Abyholm T. The impact of obesity and insulin resistance on the outcome of IVF or ICSI in women with polycystic ovarian syndrome. Hum Reprod. 2001; 16:1086-1091.
84. Davis TM, Turner RC. CIGMA assessment of insulin resistance and pancreatic beta cell function in the elderly. Age Ageing. 1985;14:220-224.
85. Davis TM, Karbwang J, Looareesuwan S, Turner RC, White NJ. Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers. Br J Pharm. 1990;30:397-403.
86. Davis TM, Pukrittayakamee S, Supanaranond W, et al. Glucose metabolism in quinine-treated patients with uncomplicated falciparum malaria. Clin Endocrinol. 1990;33:739-749.
87. Kashiwabara H, Inaba M, Maruno Y, et al. Insulin levels during fasting and the glucose tolerance test and Homa's index predict subsequent development of hypertension. J Hypertens. 2000;18:83-88.
88. Levine R, Haft D. Carbohydrate homeostasis. N Engl J Med. 1970;283:237-246.
89. Hollenbeck CB, Chen N, Chen Y-DI, Reaven GM. Relationship between the plasma insulin response to oral glucose and insulin-stimulated glucose utilization in normal subjects. Diabetes. 1984;33:460-463.
90. Cederholm J, Wibell L. Insulin release and peripheral sensitivity at the oral glucose tolerance test. Diabetes Res Clin Pract. 1990;10:167-175.
91. Gutt M, Davis CL, Spitzer SB, et al. Validation of the insulin sensitivity index (ISI 0, 120): comparison with other measures. Diabetes Res Clin Pract. 2000;47:177-184.
92. Avignon A, Boegner C, Mariano-Goulart D, Colette C, Monnier L. Assessment of insulin sensitivity from plasma insulin and glucose in the fasting or post oral glucose-load state. Int J Obes. 1999;23: 512-517.
93. Belfiore F, Iannello S, Camuto M, Fagone S, Cavaleri A. Insulin sensitivity of blood glucose versus insulin sensitivity of blood free fatty acids in normal, obese, and obese-diabetic subjects. Metabolism. 2001;50:573-582.
94. Stumvoll M, Mitrakou A, Pimenta W, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care. 2000;23:295-301.
95. Karam JH, Grodsky GM, Forsham PH. Excessive insulin response to glucose in obese subjects as measured by immunochemical assay. Diabetes. 1963;12:197-204.
96. Tura A, Ludvik B, Nolan JJ, Pacini G, Thomaseth K. Insulin and C-peptide secretion and kinetics in humans: direct and model-based measurements during OGTT. Am J Physiol Endocrinol Metab. 2001;281:E966-E974.
97. Ko GTC, Chan JCN, Woo J, et al. The reproducibility and usefulness of the oral glucose tolerance test in screening for diabetes and other cardiovascular disease. Ann Clin Biochem. 1998;35:62-67.
98. McDonald GW, Fisher GF, Burnham C. Reproducibility of the oral glucose tolerance test. Diabetes. 1965;14:473-480.
99. Horgaard A, Thayssen THE. Clinical investigation into the effect of the intravenous injection of insulin. Acta Med Scand. 1929;72:92-95.
100. Lundbaek K. Intravenous glucose tolerance as a tool in definition and diagnosis of diabetes mellitus. BMJ. 1962;2:1507.
101. Bonora E, Mogletti P, Zancanaro C, et al. Estimates of in vivo insulin action in man: comparison of insulin tolerance tests with euglycemic and hyperglycemic glucose clamp studies. J Clin Endocrinol Metab. 1989;68:374-378.
102. Del Prato S, Ferrannini E, DeFronzo RA. Evaluation of insulin sensitivity in man. In: Clark WL, Larner J, Pohl SL, eds. Methods in Diabetes Research. New York: Wiley and Sons; 1986:36-75.
103. Akinmokun A, Selby PL, Ramaiya K, Aberti KGMM. The short insulin tolerance test for determination of insulin sensitivity: a comparison with the euglycaemic clamp. Diabet Med. 1992;9:432-437.
104. Grulet H, Durlach V, Hecart AC, Gross A, Leutenegger M. Study of the rate of early glucose disappearance following insulin injection: insulin sensitivity index. Diabetes Res Clin Pract. 1993;20: 201-207.
105. Gelding SV, Robinson S, Lowe S, Niththyananthan R, Johnston DG. Validation of the low dose short insulin tolerance test for evaluation of insulin sensitivity. Clin Endocrinol. 1994;40:611-615.
106. Hirst S, Phillips DIW, Vines SK, Clark PM, Hales CN. Reproducibility of the short insulin tolerance test. Diabet Med. 1993;10:839.
107. Gonzalez-Ortiz M, Martinez-Abundis E, Pascoe-Gonzalez S. Comparison between usual and low doses of insulin in the assessment of insulin sensitivity with a short insulin tolerance test in obese women. Arch Med Res. 1999;30:385-387.
108. Young RP, Critchley JA, Anderson PJ, Lau MS, Lee KK, Chan JC. The short insulin tolerance test: feasibility study using venous sampling. Diabet Med. 1996;13:429-433.
109. Chen CC, Wang TY, Hsu SY, Chen RH, Chang CT, Chen SJ. Is the short insulin tolerance test safe and reproducible? Diabet Med. 1998;15:924-927.
110. Sarnblad S, Kroon M, Aman J. The short insulin tolerance test lacks validity in adolescents with type 1 diabetes. Diabet Med. 2002;19:51-56.
111. Gaber AJ, Cryer PE, Santiago JV, Haymond MW, Pagliara AS, Kipnis DM. The role of adrenergic mechanisms in the substrate and hormonal response to insulin-induced hypoglycemia in man. J Clin Invest. 1976;58:7.
112. Rizza RA, Cryer PE, Gerich JE. Role of glucagon, catecholamines and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha and β-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia. J Clin Invest. 1979;64:62-71.
113. Gerich J, Cryer P, Rizza R. Hormonal mechanisms in acute glucose counterregulation: the relative role of glucagon, epinephrine, norepinephrine, growth hormone and cortisol. Metabolism. 1980; 29:1164-1175.
114. Graci S, Baratta R, Degano C, et al. The intravenous insulin tolerance test is an accurate method for screening a general population for insulin resistance and related abnormalities. J Endocrinol Invest. 1999;22:472-475.
115. Borghouts LB, Backx K, Mensink MF, Keizer HA. Effect of training intensity on insulin sensitivity as evaluated by insulin tolerance test. Eur J Appl Physiol. 1999;80:461-466.
116. Gelonese B, Tambascia MA, Pareja JC, Repetto EM, Magna LA. The insulin tolerance test in morbidly obese patients undergoing bariatric surgery. Obes Res. 2001;9:763-769.
117. Bartha JL, Comino-Delgado R, Martinez-DelFresno P, Fernandez-Barrios M, Bethencourt I, Moreno-Corral L. Insulin-sensitivity index and carbohydrate and lipid metabolism in gestational diabetes. J Reprod Med. 2000;45:185-189.
118. Andres R, Swerdloff R, Pozefsky T, Coleman D. Manual feedback technique for the control of blood glucose concentration, In: Skeggs LT, eds. Automation in Analytical Chemistry. New York: Mediad; 1966:486-491.
119. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214-E223.
120. Bergman RN, Finewood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev. 1985;6: 45-86.
121. DeFronzo RA, Soman RS, Sherwin R, Hendler R, Felig P. Insulin binding to monocytes and insulin action in human obesity, starvation, and refeeding. J Clin Invest. 1978;62:204-213.
122. Groop LC, Bonadonna RC, Simonson DC, Petrides AS, Shank M, DeFronzo RA. Effect of insulin on oxidative and non-oxidative pathways of glucose and FFA metabolism in NIDDM. Evidence for multiple sites of insulin resistance. J Clin Invest. 1989;84:205-213.
123. DeFronzo RA, Ferrannini E, Hendler R, Felig P, Wahren J. Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia in man. Diabetes. 1983;32:35.
124. DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP. The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes. 1981;30:1000.
125. Paternostro G, Camici PG, Lammerstma AA, et al. Cardiac and skeletal muscle insulin resistance in patients with coronary artery disease: a study with positron-emitting tomography. J Clin Invest. 1996; 98:2094-2099.
126. Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA, Shulman RG. Quantitation of muscle glycogen synthesis in normal subjects and in subjects with non-insulin-dependent diabetes by 13 C nuclear magnetic resonance spectroscopy. N Engl J Med. 1990;322:223-228.
127. Krentz AJ. Fortnightly review: insulin resistance. BMJ. 1996;313:1385-1389.
128. Gottesman I, Mandarino L, Gerich J. Use of glucose uptake and glucose clearance for the evaluation of insulin action in vivo. Diabetes. 1984;33: 184-191.
129. Rizza RA, Mandarino LJ, Gerich JE. Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am J Physiol. 1981;240:E630-E639.
130. Stumvoll M, Gerich J. Clinical features of insulin resistance and beta cell dysfunction and the relationship to type 2 Diabetes. Clin Lab Med. 2001; 21:31-51, 2001.
131. Cagnacci A, Arangino S, Renzi A, Cagnacci P, Volpe A. Insulin sensitivity in women: a comparison among values derived from intravenous glucose tolerance tests with different sampling frequency, oral glucose test and fasting. Eur J Endocrinol. 2001;145:281-287.
132. Bergman RN, Ider YZ, Bowden CR, Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol. 1979;236:E667-E677.
133. Pacini G, Bergman RN. MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed. 1986;23:113-122.
134. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man. J Clin Invest. 1981;68:1456-1467.
135. Bergman RN. Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal model approach. Diabetes. 1989;38:1512-1527.
136. Beard JC, Bergman RN, Ward WK, Porte D Jr. The insulin sensitivity index in nondiabetic man: correlation between clamp-derived and IVGTT-derived values. Diabetes. 1986;35:362-369.
137. Osei K, Cottrell DA, Henry ML, Tesi RJ, Ferguson RM, O'Dorisio TM. Minimal model analysis of insulin sensitivity and glucose-mediated glucose disposal in type 1 (insulin-dependent) diabetic pancreas allograft recipients. Diabetologia. 1992; 35:676-680.
138. Taniguchi A, Nakai Y, Fukuzawa H, et al. Insulin sensitivity, insulin secretion, and glucose effectiveness in obese subjects: a minimal model analysis. Metabolism. 1995;44:1397-1400.
139. Saad MF, Anderson RL, Laws A, et al. A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Insulin Resistance Atherosclerosis Study. Diabetes. 1994; 43:1114-1121.
140. Finewood DT, Hramiak IM, Dupre J. A modified protocol for estimation of insulin sensitivity with the minimal model of glucose kinetics in patients with insulin-dependent diabetes. J Clin Endocrinol Metab. 1990;70:1538-1549.
141. Welch S, Gebhart SS, Bergman RN, Phillips LS. Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab. 1990;71:1508-1518.
142. Saad MF, Steil GM, Kades WW, et al. Differences between the tolbutamide-boosted and the insulin-modified minimal models protocols. Diabetes. 1997;46:1167-1171.
143. Saad MF, Steil GM, Riad-Gabriel M, et al. Method of insulin administration has no effect on insulin sensitivity estimates from the Insulin-modified Minimal Model Protocol. Diabetes. 1997;46:2044-2048.
144. Caumo A, Giacca A, Morgese M, Pozza G, Micossi P, Cobelli C. Minimal models of glucose disappearance: lessons from the labeled IVGTT. Diabet Med. 1991;8:822-832.
145. Cobelli C, Bettini F, Caumo A, Quon MJ. Overestimation of minimal model glucose effectiveness in presence of insulin response is due to undermodeling. Am J Physiol. 1998;275 E1031-E1036.
146. Quon MJ, Cochran C, Taylor SI, Eastman RG. Direct comparison of standard and insulin modified protocols for minimal model estimation of insulin sensitivity in normal subjects. Diabetes Res. 1994;25:139-149.
147. Finewood DT, Tzur D. Reduced glucose effectiveness associated with reduced insulin release: an artifact of the minimal model. Am J Physiol. 1996; 271:E485-E495.
148. Quon MJ, Cochran C, Taylor SI, Eastman RC. Non-insulin-mediated glucose disappearance in subjects with IDDM. Discordance between experimental results and minimal model analysis. Diabetes. 1994;43:890-896.
149. Hong Y, Weisnagel SJ, Rice T, et al. Familial resemblance for glucose and insulin metabolism indices derived from and intravenous glucose tolerance test in blacks and whites of the HERITAGE Family Study. Clin Genet. 2001;60:22-30.
150. Karter AJ, Mayer-Davis EJ, Selby JV, et al. Insulin sensitivity and abdominal obesity in African-American, Hispanic, and non-Hispanic white men and women. The Insulin Resistance and Atherosclerosis Study. Diabetes. 1996;45:1547-1555.
151. Haffner SM, Howard G, Mayer E, et al. Insulin sensitivity and acute insulin response in African-Americans, non-Hispanic whites, and Hispanics with NIDDM: the Insulin Resistance Atherosclerosis Study. Diabetes. 1997;46:63-69.
152. Mayer-Davis EJ, Monaco JM, Hoen HM, et al. Dietary fat and insulin sensitivity in a triethnic population: the role of obesity. The Insulin Resistance Atherosclerosis Study (IRAS). Am J Clin Nutr. 1997;65:79-87.
153. Howard G, Bergman R, Wagenknecht LE, et al. Ability of alternative indices of insulin sensitivity to predict cardiovascular risk: comparison with the "minimal model." Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Ann Epidemiol. 1998;8:358-369.
154. Foley JE, Chen YD, Lardinois CK, Hollenbeck CB, Liu GC, Reaven GM. Estimates of in vivo insulin action in humans: comparison of the insulin clamp and the minimal model techniques. Horm Metab Res. 1985;17:406-409.
155. Donner CC, Fraze E, Chen YDI, Hollenbeck CB, Foley JE, Reaven GM. Presentation of a new method for specific measurement of in vivo insulin-stimulated glucose disposal in humans: comparison of this approach with the insulin clamp and minimal model techniques. J Clin Endocrinol Metab. 1985;60:723-726.
156. Bergman RN, Prager R, Volund A, Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycaemic glucose clamp. J Clin Invest. 1987; 79:790-800.
157. Abbate SL, Fujimoto WY, Brunzell JD, Kahn SE. Effect of heparin on insulin-glucose interactions measured by the minimal model technique: implications for reproducibility using this method. Metabolism. 1993;42:353-357.
158. Ferrari P, Alleman Y, Riesen W, Weidmann P. Reproducibility of insulin sensitivity measured by the minimal model method. Diabetologia. 1991;34: 527-530.
159. Steil GM, Murray J, Bergman RN, Buchanan TA. Repeatability of insulin sensitivity and glucose effectiveness from the minimal model: implications for study design. Diabetes. 1994;43:1365-1367.
160. Duysinx BC, Scheen AJ, Gerard PL, Letiexhe MR, Paquot N, Lefebvre PJ. Measurement of insulin sensitivity by the minimal model method using a simplified intravenous glucose tolerance test: validity and reproducibility. Diabetes Metab. 1994; 20:425-432.
161. Groop LC. Insulin resistance and insulin deficiency in the pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: errors of metabolism or of methods? Diabetologia. 1993;36:1326-1331.